In	O
vivo	O
footprint	O
analysis	O
of	O
the	O
HLA-DRA	B-DNA
gene	I-DNA
promoter	I-DNA
:	O
cell-specific	O
interaction	O
at	O
the	O
octamer	B-DNA
site	I-DNA
and	O
up-regulation	O
of	O
X	O
box	O
binding	O
by	O
interferon	B-protein
gamma	I-protein
.	O

Analysis	O
of	O
the	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
promoter	I-DNA
DRA	B-DNA
has	O
previously	O
identified	O
at	O
least	O
five	O
cis-acting	B-DNA
regions	I-DNA
required	O
for	O
maximal	O
expression	O
.	O

We	O
have	O
examined	O
the	O
DRA	B-DNA
promoter	I-DNA
for	O
protein-DNA	O
interactions	O
in	O
the	O
intact	B-cell_type
cell	I-cell_type
,	O
which	O
may	O
mediate	O
transcriptional	O
activation	O
.	O

Using	O
in	O
vivo	O
genomic	O
footprinting	O
we	O
identified	O
interactions	O
in	O
B-cell	B-cell_line
lines	I-cell_line
at	O
the	O
octamer	B-DNA
site	I-DNA
and	O
the	O
Y	B-DNA
,	I-DNA
X1	I-DNA
,	I-DNA
and	I-DNA
X2	I-DNA
boxes	I-DNA
.	O

Class	B-cell_line
II	I-cell_line
antigen	I-cell_line
expressing	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
maintained	O
contacts	O
identical	O
to	O
B-cell	B-cell_line
lines	I-cell_line
,	O
while	O
class	B-cell_line
II-negative	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
exhibited	O
no	O
interactions	O
.	O

In	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
the	O
octamer	B-DNA
site	I-DNA
is	O
occupied	O
and	O
required	O
for	O
maximal	O
expression	O
.	O

This	O
is	O
most	O
likely	O
due	O
to	O
the	O
presence	O
of	O
the	O
lymphoid-specific	B-protein
OTF-2	I-protein
factor	I-protein
.	O

In	O
contrast	O
,	O
the	O
class	B-cell_line
II-positive	I-cell_line
nonlymphoid	I-cell_line
glioblastoma	I-cell_line
cell	I-cell_line
line	I-cell_line
does	O
not	O
exhibit	O
interactions	O
at	O
the	O
octamer	B-DNA
site	I-DNA
despite	O
the	O
presence	O
of	O
the	O
ubiquitous	B-protein
OTF-1	I-protein
factor	I-protein
and	O
an	O
open	B-DNA
binding	I-DNA
site	I-DNA
.	O

Thus	O
,	O
the	O
DRA	B-DNA
promoter	I-DNA
discriminates	O
against	O
OTF-1	B-protein
activation	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
in	O
the	O
glioblastoma	B-cell_line
line	I-cell_line
.	O

Interferon	B-protein
gamma	I-protein
induces	O
class	O
II	O
expression	O
in	O
this	O
glioblastoma	B-cell_line
cell	I-cell_line
line	I-cell_line
and	O
,	O
in	O
parallel	O
,	O
up-regulates	O
X1	O
and	O
X2	O
box	O
protein-DNA	O
interactions	O
,	O
while	O
all	O
other	O
interactions	O
remain	O
unchanged	O
.	O

These	O
results	O
suggest	O
that	O
interferon	B-protein
gamma	I-protein
functions	O
on	O
a	O
poised	B-DNA
promoter	I-DNA
by	O
altering	O
weak	O
,	O
nonproductive	O
interactions	O
at	O
the	O
X	B-DNA
boxes	I-DNA
to	O
strong	O
interactions	O
.	O

These	O
findings	O
provide	O
direct	O
in	O
vivo	O
evidence	O
to	O
strongly	O
suggest	O
that	O
the	O
modulation	O
of	O
X1	B-DNA
and	O
X2	B-DNA
interactions	O
is	O
an	O
important	O
constituent	O
of	O
the	O
interferon	B-protein
gamma	I-protein
induction	O
pathway	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

89	NULL
,	NULL
pp	NULL
.	NULL

7601-7605	NULL
,	NULL
August	NULL
1992	NULL
Biochemistry	NULL
In	NULL
vivo	NULL
footprint	NULL
analysis	NULL
of	NULL
the	NULL
HLA-DRA	NULL
gene	NULL
promoter	NULL
:	NULL
Cell-specific	NULL
interaction	NULL
at	NULL
the	NULL
octamer	NULL
site	NULL
and	NULL
up-regulation	NULL
of	NULL
X	NULL
box	NULL
binding	NULL
by	NULL
interferon	NULL
y	NULL
(	NULL
in	NULL
vivo	NULL
genomic	NULL
footprinting	NULL
/major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
II	NULL
genes	NULL
/octamer	NULL
binding	NULL
proteins	NULL
)	NULL
KENNETH	NULL
L.	NULL
WRIGHT	NULL
AND	NULL
JEnny	NULL
P.-Y	NULL
.	NULL

Ting	NULL
University	NULL
of	NULL
North	NULL
Carolina	NULL
Lineberger	NULL
Comprehensive	NULL
Cancer	NULL
Center	NULL
,	NULL
Department	NULL
of	NULL
Microbiology-Immunology	NULL
,	NULL
University	NULL
of	NULL
North	NULL
Carolina	NULL
at	NULL
Chapel	NULL
Hill	NULL
,	NULL
Chapel	NULL
Hill	NULL
,	NULL
NC	NULL
27599	NULL
Communicated	NULL
by	NULL
Ray	NULL
D.	NULL
Owen	NULL
,	NULL
May	NULL
20	NULL
,	NULL
1992	NULL
(	NULL
received	NULL
for	NULL
review	NULL
December	NULL
16	NULL
,	NULL
1991	NULL
)	NULL
ABSTRACT	NULL
Analysis	NULL
of	NULL
the	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
II	NULL
gene	NULL
promoter	NULL
DRA	NULL
has	NULL
previously	NULL
identified	NULL
at	NULL
least	NULL
five	NULL
cis-acting	NULL
regions	NULL
required	NULL
for	NULL
maximal	NULL
expression	NULL
.	NULL

We	NULL
have	NULL
examined	NULL
the	NULL
DRA	NULL
promoter	NULL
for	NULL
protein-DNA	NULL
interactions	NULL
in	NULL
the	NULL
intact	NULL
cell	NULL
,	NULL
which	NULL
may	NULL
mediate	NULL
transcriptional	NULL
activation	NULL
.	NULL

Using	NULL
in	NULL
vivo	NULL
genomic	NULL
footprinting	NULL
we	NULL
identified	NULL
interactions	NULL
in	NULL
B-cell	NULL
lines	NULL
at	NULL
the	NULL
octamer	NULL
site	NULL
and	NULL
the	NULL
Y	NULL
,	NULL
X	NULL
;	NULL
,	NULL
and	NULL
X	NULL
;	NULL
boxes	NULL
.	NULL

Class	NULL
II	NULL
antigen	NULL
expressing	NULL
T-cell	NULL
lines	NULL
maintained	NULL
contacts	NULL
identical	NULL
to	NULL
B-cell	NULL
lines	NULL
,	NULL
while	NULL
class	NULL
II-negative	NULL
T-cell	NULL
lines	NULL
exhibited	NULL
no	NULL
interactions	NULL
.	NULL

In	NULL
lymphoid	NULL
cell	NULL
lines	NULL
,	NULL
the	NULL
octamer	NULL
site	NULL
is	NULL
occupied	NULL
and	NULL
required	NULL
for	NULL
maximal	NULL
expression	NULL
.	NULL

This	NULL
is	NULL
most	NULL
likely	NULL
due	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
lymphoid-specific	NULL
OTF-2	NULL
factor	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
class	NULL
II-positive	NULL
nonlymphoid	NULL
glioblastoma	NULL
cell	NULL
line	NULL
does	NULL
not	NULL
exhibit	NULL
interactions	NULL
at	NULL
the	NULL
octamer	NULL
site	NULL
despite	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
ubiquitous	NULL
OTF-1	NULL
factor	NULL
and	NULL
an	NULL
open	NULL
binding	NULL
site	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
DRA	NULL
promoter	NULL
discriminates	NULL
against	NULL
OTF-1	NULL
activation	NULL
at	NULL
the	NULL
level	NULL
of	NULL
DNA	NULL
binding	NULL
in	NULL
the	NULL
glioblastoma	NULL
line	NULL
.	NULL

Interferon	NULL
y	NULL
induces	NULL
class	NULL
II	NULL
expression	NULL
in	NULL
this	NULL
cell	NULL
line	NULL
and	NULL
,	NULL
in	NULL
parallel	NULL
,	NULL
up-regulates	NULL
X	NULL
,	NULL
and	NULL
X	NULL
;	NULL
box	NULL
protein-DNA	NULL
interactions	NULL
,	NULL
while	NULL
all	NULL
other	NULL
interactions	NULL
remain	NULL
unchanged	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
interferon	NULL
y	NULL
functions	NULL
on	NULL
a	NULL
poised	NULL
promoter	NULL
by	NULL
altering	NULL
weak	NULL
,	NULL
nonproductive	NULL
interactions	NULL
at	NULL
the	NULL
X	NULL
boxes	NULL
to	NULL
strong	NULL
interactions	NULL
.	NULL

These	NULL
findings	NULL
provide	NULL
direct	NULL
in	NULL
vivo	NULL
evidence	NULL
to	NULL
strongly	NULL
suggest	NULL
that	NULL
the	NULL
modulation	NULL
of	NULL
X	NULL
,	NULL
and	NULL
X	NULL
;	NULL
interactions	NULL
is	NULL
an	NULL
important	NULL
constituent	NULL
of	NULL
the	NULL
interferon	NULL
y	NULL
induction	NULL
pathway	NULL
.	NULL

The	NULL
major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
class	NULL
II	NULL
molecules	NULL
play	NULL
a	NULL
central	NULL
role	NULL
in	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

MHC	NULL
class	NULL
II	NULL
molecules	NULL
can	NULL
present	NULL
antigen	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
cells	NULL
,	NULL
which	NULL
is	NULL
then	NULL
recognized	NULL
by	NULL
the	NULL
T-cell	NULL
receptor	NULL
of	NULL
class	NULL
II-restricted	NULL
T	NULL
cells	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

This	NULL
interaction	NULL
leads	NULL
to	NULL
an	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
and	NULL
the	NULL
initiation	NULL
of	NULL
an	NULL
immune	NULL
response	NULL
.	NULL

The	NULL
intensity	NULL
of	NULL
the	NULL
response	NULL
is	NULL
modulated	NULL
by	NULL
the	NULL
level	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

Specific	NULL
haplotypes	NULL
of	NULL
class	NULL
II	NULL
have	NULL
been	NULL
linked	NULL
to	NULL
several	NULL
autoimmune	NULL
diseases	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
a	NULL
detailed	NULL
investigation	NULL
of	NULL
the	NULL
regulation	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
antigen	NULL
expression	NULL
is	NULL
critical	NULL
to	NULL
our	NULL
understanding	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
and	NULL
immune	NULL
system	NULL
dysfunction	NULL
.	NULL

Class	NULL
II	NULL
molecules	NULL
are	NULL
expressed	NULL
on	NULL
a	NULL
select	NULL
group	NULL
of	NULL
cell	NULL
types	NULL
including	NULL
B	NULL
cells	NULL
,	NULL
dendritic	NULL
cells	NULL
,	NULL
thymic	NULL
epithelial	NULL
cells	NULL
,	NULL
skin	NULL
Langerhans	NULL
cells	NULL
,	NULL
liver	NULL
Kupffer	NULL
cells	NULL
,	NULL
brain	NULL
glial	NULL
cells	NULL
(	NULL
6-8	NULL
)	NULL
,	NULL
and	NULL
activated	NULL
macrophages	NULL
and	NULL
T	NULL
cells	NULL
(	NULL
9-12	NULL
)	NULL
.	NULL

Cytokines	NULL
such	NULL
as	NULL
interferon	NULL
y	NULL
(	NULL
IFN-y	NULL
)	NULL
can	NULL
induce	NULL
class	NULL
II	NULL
expression	NULL
in	NULL
a	NULL
small	NULL
number	NULL
of	NULL
class	NULL
II-negative	NULL
cell	NULL
types	NULL
(	NULL
13-16	NULL
)	NULL
.	NULL

In	NULL
most	NULL
cases	NULL
,	NULL
class	NULL
II	NULL
expression	NULL
is	NULL
regulated	NULL
primarily	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
,	NULL
prompting	NULL
extensive	NULL
study	NULL
of	NULL
the	NULL
promoter	NULL
regions	NULL
and	NULL
in	NULL
particular	NULL
the	NULL
HLA-DRA	NULL
promoter	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

ยง1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

7601	NULL
Two	NULL
highly	NULL
conserved	NULL
promoter	NULL
domains	NULL
termed	NULL
the	NULL
X	NULL
and	NULL
Y	NULL
boxes	NULL
lie	NULL
within	NULL
the	NULL
proximal	NULL
promoter	NULL
region	NULL
of	NULL
class	NULL
II	NULL
genes	NULL
(	NULL
17	NULL
)	NULL
.	NULL

These	NULL
elements	NULL
are	NULL
critical	NULL
for	NULL
optimal	NULL
class	NULL
II	NULL
gene	NULL
expression	NULL
(	NULL
18-21	NULL
)	NULL
.	NULL

The	NULL
X	NULL
box	NULL
interacts	NULL
in	NULL
vitro	NULL
with	NULL
at	NULL
least	NULL
two	NULL
proteins	NULL
,	NULL
RF-X	NULL
and	NULL
hXBP-1	NULL
.	NULL

RF-X	NULL
binds	NULL
over	NULL
the	NULL
5	NULL
end	NULL
of	NULL
the	NULL
X	NULL
box	NULL
(	NULL
X	NULL
;	NULL
)	NULL
and	NULL
has	NULL
aberrant	NULL
binding	NULL
in	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
the	NULL
bare	NULL
lymphocyte	NULL
syndrome	NULL
(	NULL
22	NULL
,	NULL
23	NULL
)	NULL
.	NULL

hXBP-1	NULL
binds	NULL
at	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
the	NULL
X	NULL
box	NULL
(	NULL
X	NULL
;	NULL
)	NULL
and	NULL
has	NULL
homology	NULL
to	NULL
Fos	NULL
and	NULL
Jun	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Functional	NULL
analysis	NULL
with	NULL
site-specific	NULL
mutations	NULL
has	NULL
indicated	NULL
that	NULL
both	NULL
X	NULL
;	NULL
and	NULL
X	NULL
ยป	NULL
are	NULL
important	NULL
for	NULL
the	NULL
constitutive	NULL
level	NULL
of	NULL
transcription	NULL
and	NULL
X	NULL
,	NULL
is	NULL
involved	NULL
in	NULL
IFN-y	NULL
inducibility	NULL
(	NULL
24	NULL
,	NULL
25	NULL
)	NULL
.	NULL

The	NULL
Y	NULL
box	NULL
contains	NULL
an	NULL
inverted	NULL
CCAAT	NULL
motif	NULL
with	NULL
which	NULL
several	NULL
proteins	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
interact	NULL
in	NULL
vitro	NULL
.	NULL

YEBP	NULL
was	NULL
partially	NULL
purified	NULL
in	NULL
our	NULL
laboratory	NULL
from	NULL
B-cell	NULL
extracts	NULL
and	NULL
activates	NULL
the	NULL
DRA	NULL
promoter	NULL
in	NULL
vitro	NULL
(	NULL
20	NULL
)	NULL
.	NULL

YEBP	NULL
may	NULL
be	NULL
the	NULL
human	NULL
analog	NULL
to	NULL
the	NULL
murine	NULL
NF-Y	NULL
A/B	NULL
(	NULL
26	NULL
,	NULL
27	NULL
)	NULL
.	NULL

YB-1	NULL
was	NULL
cloned	NULL
from	NULL
an	NULL
expression	NULL
library	NULL
and	NULL
,	NULL
while	NULL
its	NULL
DNA	NULL
recognition	NULL
site	NULL
is	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
YEBP	NULL
and	NULL
NF-Y	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
YB-1	NULL
is	NULL
inversely	NULL
correlated	NULL
to	NULL
the	NULL
level	NULL
of	NULL
class	NULL
II	NULL
expression	NULL
,	NULL
implying	NULL
a	NULL
potential	NULL
role	NULL
as	NULL
a	NULL
negative	NULL
regulator	NULL
(	NULL
28	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
X	NULL
and	NULL
Y	NULL
boxes	NULL
,	NULL
the	NULL
DRA	NULL
promoter	NULL
is	NULL
unique	NULL
within	NULL
the	NULL
class	NULL
II	NULL
family	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
octamer	NULL
binding	NULL
site	NULL
between	NULL
the	NULL
Y	NULL
and	NULL
TATA	NULL
boxes	NULL
.	NULL

This	NULL
site	NULL
is	NULL
functionally	NULL
required	NULL
in	NULL
B	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
most	NULL
nonlymphoid	NULL
cell	NULL
types	NULL
(	NULL
18	NULL
,	NULL
29	NULL
,	NULL
30	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
less-conserved	NULL
functional	NULL
domain	NULL
,	NULL
W	NULL
,	NULL
lies	NULL
upstream	NULL
of	NULL
the	NULL
X	NULL
box	NULL
.	NULL

Functional	NULL
analysis	NULL
of	NULL
this	NULL
region	NULL
has	NULL
identified	NULL
a	NULL
Servenius	NULL
sequence	NULL
(	NULL
S	NULL
)	NULL
,	NULL
which	NULL
is	NULL
required	NULL
for	NULL
IFN-y	NULL
responsiveness	NULL
(	NULL
31-33	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
protein-DNA	NULL
studies	NULL
are	NULL
limited	NULL
because	NULL
they	NULL
may	NULL
not	NULL
accurately	NULL
reflect	NULL
the	NULL
in	NULL
vivo	NULL
state	NULL
of	NULL
promoter	NULL
interactions	NULL
.	NULL

The	NULL
recent	NULL
improvement	NULL
of	NULL
the	NULL
in	NULL
vivo	NULL
genomic	NULL
footprinting	NULL
procedure	NULL
(	NULL
34	NULL
)	NULL
permits	NULL
analysis	NULL
of	NULL
protein-DNA	NULL
interactions	NULL
in	NULL
intact	NULL
cells	NULL
.	NULL

This	NULL
report	NULL
utilizes	NULL
in	NULL
vivo	NULL
genomic	NULL
footprinting	NULL
to	NULL
confirm	NULL
initial	NULL
findings	NULL
in	NULL
B	NULL
cells	NULL
(	NULL
35	NULL
)	NULL
and	NULL
expands	NULL
it	NULL
to	NULL
class	NULL
II-positive	NULL
and	NULL
class	NULL
II-negative	NULL
T-cell	NULL
lines	NULL
.	NULL

Analysis	NULL
of	NULL
an	NULL
inducible	NULL
,	NULL
nonlymphoid	NULL
cell	NULL
line	NULL
revealed	NULL
the	NULL
selective	NULL
lack	NULL
of	NULL
interaction	NULL
at	NULL
the	NULL
octamer	NULL
site	NULL
despite	NULL
the	NULL
availability	NULL
of	NULL
the	NULL
ubiquitous	NULL
octamer	NULL
binding	NULL
factor	NULL
OTF-1	NULL
and	NULL
an	NULL
open	NULL
binding	NULL
site	NULL
.	NULL

Most	NULL
importantly	NULL
,	NULL
this	NULL
analysis	NULL
demonstrated	NULL
that	NULL
IFN-y	NULL
induction	NULL
of	NULL
class	NULL
II	NULL
antigen	NULL
expression	NULL
is	NULL
characterized	NULL
by	NULL
an	NULL
up-regulation	NULL
of	NULL
X1	NULL
and	NULL
X	NULL
;	NULL
box	NULL
interactions	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
Lines	NULL
,	NULL
Reagents	NULL
,	NULL
and	NULL
DNA	NULL
Constructs	NULL
.	NULL

Raji	NULL
and	NULL
Namalwa	NULL
are	NULL
human	NULL
Burkitt	NULL
lymphoma	NULL
B-cell	NULL
lines	NULL
that	NULL
express	NULL
Abbreviations	NULL
:	NULL
MHC	NULL
,	NULL
major	NULL
histocompatibility	NULL
complex	NULL
;	NULL
IFN-y	NULL
,	NULL
interferon	NULL
y	NULL
;	NULL
T-LCL	NULL
,	NULL
T-lymphoblastoid	NULL
cell	NULL
line	NULL
;	NULL
B-LCL	NULL
,	NULL
B-lymphoblastoid	NULL
cell	NULL
line	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
;	NULL
DMS	NULL
,	NULL
dimethyl	NULL
sulfate	NULL
.	NULL

7602	NULL
Biochemistry	NULL
:	NULL
Wright	NULL
and	NULL
Ting	NULL
high	NULL
levels	NULL
of	NULL
class	NULL
II	NULL
antigens	NULL
.	NULL

H9	NULL
(	NULL
HuT78	NULL
)	NULL
was	NULL
derived	NULL
from	NULL
a	NULL
human	NULL
cutaneous	NULL
T-cell	NULL
lymphoma	NULL
and	NULL
constitutively	NULL
expresses	NULL
class	NULL
II	NULL
antigens	NULL
.	NULL

HSB	NULL
and	NULL
Jurkat	NULL
are	NULL
T-lymphoblastoid	NULL
cell	NULL
lines	NULL
(	NULL
T-LCLs	NULL
)	NULL
that	NULL
can	NULL
not	NULL
be	NULL
induced	NULL
to	NULL
express	NULL
class	NULL
II	NULL
antigens	NULL
.	NULL

U373-MG	NULL
is	NULL
a	NULL
glioblastoma	NULL
multiform	NULL
cell	NULL
line	NULL
(	NULL
36	NULL
)	NULL
.	NULL

The	NULL
human	NULL
recombinant	NULL
IFN-y	NULL
was	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Biogen	NULL
.	NULL

The	NULL
wild-type	NULL
DRA	NULL
promoter-chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
fusion	NULL
construct	NULL
(	NULL
5	NULL
'	NULL
A-152	NULL
WT	NULL
)	NULL
has	NULL
been	NULL
described	NULL
(	NULL
33	NULL
)	NULL
.	NULL

The	NULL
5	NULL
'	NULL
A-152	NULL
MUTocta	NULL
construct	NULL
was	NULL
generated	NULL
by	NULL
site-directed	NULL
mutagenesis	NULL
(	NULL
37	NULL
)	NULL
and	NULL
altered	NULL
octamer	NULL
motif	NULL
from	NULL
S'-TTGATTTGCAT-3	NULL
'	NULL
to	NULL
5'-TTGegegt-CAT-3	NULL
'	NULL
.	NULL

In	NULL
Vivo	NULL
Footprinting	NULL
.	NULL

In	NULL
vivo	NULL
methylation	NULL
of	NULL
cells	NULL
and	NULL
DNA	NULL
preparation	NULL
were	NULL
as	NULL
described	NULL
by	NULL
Pfeifer	NULL
et	NULL
al	NULL
.	NULL

(	NULL
38	NULL
)	NULL
.	NULL

The	NULL
ligation-mediated	NULL
,	NULL
PCR-amplified	NULL
,	NULL
in	NULL
vivo	NULL
genomic	NULL
footprinting	NULL
was	NULL
as	NULL
described	NULL
by	NULL
Mueller	NULL
and	NULL
Wold	NULL
(	NULL
34	NULL
)	NULL
except	NULL
the	NULL
initial	NULL
denaturation	NULL
was	NULL
for	NULL
10	NULL
min	NULL
at	NULL
95ยฐC	NULL
and	NULL
the	NULL
samples	NULL
were	NULL
resolved	NULL
on	NULL
a	NULL
6	NULL
%	NULL
denaturing	NULL
polyacrylamide	NULL
wedge	NULL
gel	NULL
.	NULL

The	NULL
primers	NULL
to	NULL
reveal	NULL
the	NULL
upper	NULL
strand	NULL
with	NULL
the	NULL
associated	NULL
annealing	NULL
temperature	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
upper	NULL
1	NULL
,	NULL
5'-AGG-GACTCCACTTATGGA-3	NULL
'	NULL
(	NULL
60ยฐC	NULL
)	NULL
;	NULL
upper	NULL
2	NULL
,	NULL
5-TGGGAG-TCAGTAGAGCTCGGGAGTG-3	NULL
'	NULL
(	NULL
66ยฐC	NULL
)	NULL
;	NULL
upper	NULL
3	NULL
,	NULL
5'-GAGTCAGTAGAGCTCGGGAGTGAGGCAG-3	NULL
'	NULL
(	NULL
68ยฐC	NULL
)	NULL
.	NULL

The	NULL
primers	NULL
to	NULL
reveal	NULL
the	NULL
lower	NULL
strand	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
lower	NULL
1	NULL
,	NULL
5-GTATATCCCTGTCTAGAAG-3	NULL
'	NULL
(	NULL
56ยฐC	NULL
)	NULL
;	NULL
lower	NULL
2	NULL
,	NULL
5'-GTCAGATTGGGGTTAAAGAGTCTGTCCG-3	NULL
'	NULL
(	NULL
64ยฐC	NULL
)	NULL
;	NULL
lower	NULL
3	NULL
,	NULL
5-GATTGGGGTTAAAGAGTCTGTCCGTCAT-TGAC-3	NULL
'	NULL
(	NULL
65ยฐC	NULL
)	NULL
.	NULL

Transfection	NULL
and	NULL
CAT	NULL
Reporter	NULL
Analysis	NULL
.	NULL

Cell	NULL
lines	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
test	NULL
plasmid	NULL
using	NULL
a	NULL
Bio-Rad	NULL
Gene	NULL
Pulser	NULL
electroporation	NULL
apparatus	NULL
,	NULL
and	NULL
plasmid	NULL
expression	NULL
was	NULL
assayed	NULL
by	NULL
CAT	NULL
activity	NULL
as	NULL
described	NULL
(	NULL
19	NULL
)	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
resolved	NULL
on	NULL
thin-layer	NULL
chromatography	NULL
plates	NULL
and	NULL
quantitated	NULL
with	NULL
an	NULL
Ambis	NULL
Radioanalytic	NULL
Image	NULL
Processor	NULL
.	NULL

Nuclear	NULL
Extract	NULL
Preparation	NULL
and	NULL
Gel	NULL
Mobility-Shift	NULL
Assay	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
according	NULL
to	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

(	NULL
39	NULL
)	NULL
.	NULL

The	NULL
gel	NULL
mobility-shift	NULL
assay	NULL
was	NULL
performed	NULL
essentially	NULL
as	NULL
described	NULL
by	NULL
Gerster	NULL
et	NULL
al	NULL
.	NULL

(	NULL
40	NULL
)	NULL
except	NULL
samples	NULL
were	NULL
resolved	NULL
on	NULL
a	NULL
4	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
with	NULL
TGE	NULL
buffer	NULL
(	NULL
25	NULL
mM	NULL
TrisHC1	NULL
,	NULL
pH	NULL
7.9/190	NULL
mM	NULL
glycine/1	NULL
mM	NULL
EDTA	NULL
)	NULL
.	NULL

The	NULL
probe	NULL
was	NULL
a	NULL
30-base-pair	NULL
synthetic	NULL
double-stranded	NULL
oligonucleotide	NULL
that	NULL
encompasses	NULL
the	NULL
octamer	NULL
element	NULL
of	NULL
the	NULL
DRA	NULL
promoter	NULL
and	NULL
its	NULL
flanking	NULL
sequences	NULL
.	NULL

RESULTS	NULL
A	NULL
number	NULL
of	NULL
cis-acting	NULL
DNA	NULL
elements	NULL
within	NULL
the	NULL
proximal	NULL
150	NULL
base	NULL
pairs	NULL
of	NULL
the	NULL
DRA	NULL
promoter	NULL
have	NULL
been	NULL
previously	NULL
described	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

This	NULL
report	NULL
directly	NULL
assays	NULL
the	NULL
protein-DNA	NULL
interactions	NULL
at	NULL
the	NULL
endogenous	NULL
DRA	NULL
promoter	NULL
by	NULL
in	NULL
vivo	NULL
genomic	NULL
footprinting	NULL
.	NULL

In	NULL
Vivo	NULL
,	NULL
the	NULL
DRA	NULL
Promoter	NULL
Maintains	NULL
Protein-DNA	NULL
Interactions	NULL
Across	NULL
the	NULL
Class	NULL
II	NULL
Box	NULL
and	NULL
at	NULL
the	NULL
Octamer	NULL
Site	NULL
in	NULL
Class	NULL
II-Expressing	NULL
B-Lymphoblastoid	NULL
Cells	NULL
.	NULL

Most	NULL
functional	NULL
analysis	NULL
of	NULL
the	NULL
DRA	NULL
promoter	NULL
has	NULL
been	NULL
performed	NULL
in	NULL
B-lymphoblastoid	NULL
cell	NULL
lines	NULL
(	NULL
B-LCLs	NULL
)	NULL
,	NULL
which	NULL
constitutively	NULL
express	NULL
high	NULL
levels	NULL
of	NULL
class	NULL
II	NULL
antigen	NULL
.	NULL

Thus	NULL
,	NULL
we	NULL
chose	NULL
to	NULL
initially	NULL
examine	NULL
the	NULL
in	NULL
vivo	NULL
protein-DNA	NULL
interactions	NULL
in	NULL
the	NULL
B-LCLs	NULL
Raji	NULL
and	NULL
Namalwa	NULL
.	NULL

In	NULL
vivo	NULL
genomic	NULL
footprinting	NULL
reveals	NULL
the	NULL
close	NULL
association	NULL
of	NULL
protein	NULL
with	NULL
DNA	NULL
in	NULL
the	NULL
intact	NULL
cell	NULL
by	NULL
the	NULL
protection	NULL
or	NULL
enhancement	NULL
of	NULL
dimethyl	NULL
sulfate	NULL
methylation	NULL
of	NULL
guanine	NULL
residues	NULL
(	NULL
34	NULL
,	NULL
41	NULL
)	NULL
.	NULL

These	NULL
protections	NULL
or	NULL
enhancements	NULL
are	NULL
then	NULL
displayed	NULL
as	NULL
alterations	NULL
in	NULL
the	NULL
intensity	NULL
of	NULL
specific	NULL
bands	NULL
in	NULL
the	NULL
guanine	NULL
sequence	NULL
ladder	NULL
as	NULL
compared	NULL
to	NULL
deproteinized	NULL
DNA	NULL
.	NULL

Class	NULL
II	NULL
antigen	NULL
expressing	NULL
B-LCLs	NULL
displayed	NULL
a	NULL
series	NULL
of	NULL
guanine	NULL
contact	NULL
points	NULL
on	NULL
both	NULL
the	NULL
upper	NULL
and	NULL
lower	NULL
strand	NULL
of	NULL
the	NULL
DRA	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
;	NULL
summarized	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Both	NULL
Raji	NULL
and	NULL
Namalwa	NULL
cells	NULL
revealed	NULL
identical	NULL
patterns	NULL
of	NULL
interaction	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
(	NULL
1992	NULL
)	NULL
ss	NULL
๏ฌ	NULL
1	NULL
i	NULL
ยซ	NULL
)	NULL
f	NULL
as	NULL
x	NULL
,	NULL
sas	NULL
MBB	NULL
o	NULL
%	NULL
โ	NULL
w	NULL
|	NULL
ses	NULL
.	NULL

B	NULL
x	NULL
>	NULL
|-	NULL
W	NULL
t	NULL
wha	NULL
i	NULL
B	NULL
~-	NULL
k	NULL
|	NULL
wae	NULL
nee	NULL
5	NULL
#	NULL
*	NULL
a	NULL
E	NULL
wan	NULL
wae	NULL
ยฎ	NULL
a	NULL
|_	NULL
ยฎ	NULL
c	NULL
[	NULL
~	NULL
W	NULL
WB	NULL
me	NULL
w	NULL
p	NULL
@	NULL
ao	NULL
=	NULL
we	NULL
c	NULL
a	NULL
fms	NULL
poss	NULL
ase	NULL
=a	NULL
is	NULL
me	NULL
-	NULL
se	NULL
-	NULL
8	NULL
te	NULL
+=	NULL
*	NULL
ian	NULL
_-	NULL
C	NULL
>	NULL
#	NULL
1	NULL
we	NULL
wire	NULL
h	NULL
P	NULL
ie	NULL
i	NULL
Mi	NULL
'	NULL
#	NULL
wo	NULL
th	NULL
'	NULL
=a	NULL
ยป	NULL
fm	NULL
a	NULL
wan	NULL
lits	NULL
a	NULL
&	NULL
.	NULL

--	NULL
``	NULL
o	NULL
e	NULL
&	NULL
P	NULL
โฌ	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

-	NULL
In	NULL
vivo	NULL
genomic	NULL
footprints	NULL
of	NULL
the	NULL
HLA-DRA	NULL
promoter	NULL
in	NULL
B-	NULL
and	NULL
T-LCLs	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Upper	NULL
strand	NULL
of	NULL
the	NULL
DRA	NULL
promoter	NULL
revealed	NULL
by	NULL
using	NULL
the	NULL
upper	NULL
primer	NULL
set	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

Control	NULL
,	NULL
in	NULL
vitro	NULL
methylated	NULL
deproteinized	NULL
DNA	NULL
;	NULL
DMS	NULL
,	NULL
in	NULL
vivo	NULL
methylated	NULL
DNA	NULL
(	NULL
dimethyl	NULL
sulfate	NULL
)	NULL
.	NULL

Open	NULL
circles	NULL
,	NULL
protection	NULL
;	NULL
solid	NULL
circles	NULL
,	NULL
enhance-ment	NULL
.	NULL

Functionally	NULL
defined	NULL
DNA	NULL
domains	NULL
are	NULL
indicated	NULL
on	NULL
the	NULL
left	NULL
.	NULL

Contact	NULL
points	NULL
are	NULL
indicated	NULL
for	NULL
the	NULL
first	NULL
pair	NULL
of	NULL
lanes	NULL
and	NULL
are	NULL
identical	NULL
in	NULL
the	NULL
B-LCLs	NULL
Namaiwa	NULL
and	NULL
Raji	NULL
and	NULL
in	NULL
the	NULL
T-LCL	NULL
H9	NULL
.	NULL

The	NULL
class	NULL
II-negative	NULL
Jurkat	NULL
T-LCL	NULL
exhibited	NULL
no	NULL
protein-DNA	NULL
contacts	NULL
.	NULL

Approximately	NULL
50-60	NULL
%	NULL
protection	NULL
of	NULL
the	NULL
octamer	NULL
element	NULL
was	NULL
consistently	NULL
observed	NULL
in	NULL
Namalwa	NULL
,	NULL
Raji	NULL
,	NULL
and	NULL
H9	NULL
.	NULL

Note	NULL
that	NULL
the	NULL
Raji	NULL
and	NULL
Namalwa	NULL
DMS	NULL
lanes	NULL
are	NULL
darker	NULL
overall	NULL
than	NULL
the	NULL
corresponding	NULL
control	NULL
lanes	NULL
.	NULL

The	NULL
weak	NULL
octamer	NULL
protection	NULL
seen	NULL
in	NULL
lane	NULL
8	NULL
(	NULL
Jurkat	NULL
)	NULL
was	NULL
not	NULL
reproducible	NULL
.	NULL

Contact	NULL
points	NULL
for	NULL
the	NULL
upper	NULL
strand	NULL
from	NULL
bottom	NULL
to	NULL
top	NULL
are	NULL
-48	NULL
,	NULL
-53	NULL
,	NULL
-67	NULL
,	NULL
-68	NULL
,	NULL
-83	NULL
,	NULL
-93	NULL
,	NULL
-95	NULL
,	NULL
-104	NULL
,	NULL
-117	NULL
,	NULL
and	NULL
-150	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Lower	NULL
strand	NULL
revealed	NULL
with	NULL
lower	NULL
primer	NULL
set	NULL
.	NULL

Lane	NULL
markings	NULL
are	NULL
the	NULL
same	NULL
as	NULL
in	NULL
A	NULL
.	NULL

Contact	NULL
points	NULL
for	NULL
the	NULL
lower	NULL
strand	NULL
from	NULL
top	NULL
to	NULL
bottom	NULL
are	NULL
-47	NULL
,	NULL
-88	NULL
,	NULL
-91	NULL
,	NULL
-94	NULL
,	NULL
-100	NULL
,	NULL
-103	NULL
,	NULL
-107	NULL
,	NULL
and	NULL
-108	NULL
.	NULL

&	NULL
L	NULL
L	NULL
U	NULL
I	NULL
t	NULL
1	NULL
I	NULL
1H	NULL
H	NULL
1	NULL
U	NULL
I|	NULL
H	NULL
#	NULL
E4	NULL
Two	NULL
protections	NULL
on	NULL
the	NULL
upper	NULL
strand	NULL
at	NULL
-48	NULL
and	NULL
-53	NULL
and	NULL
one	NULL
on	NULL
the	NULL
lower	NULL
strand	NULL
at	NULL
-47	NULL
are	NULL
located	NULL
at	NULL
the	NULL
octamer	NULL
consensus	NULL
sequence	NULL
.	NULL

The	NULL
lower-strand	NULL
protection	NULL
was	NULL
significantly	NULL
weaker	NULL
(	NULL
40-50	NULL
%	NULL
protection	NULL
in	NULL
Namalwa	NULL
cells	NULL
)	NULL
;	NULL
however	NULL
,	NULL
it	NULL
was	NULL
highly	NULL
reproducible	NULL
through	NULL
several	NULL
(	NULL
>	NULL
5	NULL
)	NULL
independent	NULL
experiments	NULL
.	NULL

The	NULL
octamer	NULL
sequence	NULL
is	NULL
required	NULL
for	NULL
maximal	NULL
expression	NULL
of	NULL
DRA	NULL
in	NULL
B	NULL
cells	NULL
(	NULL
see	NULL
below	NULL
and	NULL
ref	NULL
.	NULL

29	NULL
)	NULL
.	NULL

A	NULL
doublet	NULL
of	NULL
protected	NULL
guanine	NULL
residues	NULL
at	NULL
-67	NULL
and	NULL
-68	NULL
I	NULL
17/57	NULL
)	NULL
โ	NULL
ACC	NULL
AckaTaAApeteรฉc	NULL
ATA-t	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Schematic	NULL
of	NULL
HLA-DRA	NULL
promoter	NULL
and	NULL
in	NULL
vivo	NULL
contact	NULL
points	NULL
.	NULL

Shaded	NULL
boxes	NULL
,	NULL
functionally	NULL
defined	NULL
DNA	NULL
elements	NULL
;	NULL
long	NULL
arrows	NULL
,	NULL
strong	NULL
protections	NULL
;	NULL
short	NULL
arrows	NULL
,	NULL
weak	NULL
partial	NULL
protections	NULL
;	NULL
arrowheads	NULL
,	NULL
enhancements	NULL
.	NULL

X1	NULL
and	NULL
X	NULL
;	NULL
boxes	NULL
are	NULL
shown	NULL
as	NULL
independent	NULL
regions	NULL
,	NULL
although	NULL
they	NULL
may	NULL
be	NULL
overlapping	NULL
as	NULL
depicted	NULL
in	NULL
Figs	NULL
.	NULL

1	NULL
and	NULL
3	NULL
.	NULL

Small	NULL
dots	NULL
between	NULL
strands	NULL
represent	NULL
10-base-pair	NULL
increments	NULL
starting	NULL
from	NULL
the	NULL
transcription	NULL
initiation	NULL
site	NULL
.	NULL

Biochemistry	NULL
:	NULL
Wright	NULL
and	NULL
Ting	NULL
of	NULL
the	NULL
upper	NULL
strand	NULL
corresponds	NULL
to	NULL
the	NULL
inverted	NULL
CCAAT	NULL
motif	NULL
in	NULL
the	NULL
Y	NULL
box	NULL
.	NULL

Mutation	NULL
of	NULL
these	NULL
residues	NULL
has	NULL
been	NULL
shown	NULL
(	NULL
19	NULL
,	NULL
42	NULL
)	NULL
to	NULL
diminish	NULL
expression	NULL
from	NULL
the	NULL
DRA	NULL
promoter	NULL
.	NULL

The	NULL
large	NULL
19-base-pair	NULL
region	NULL
encompassing	NULL
the	NULL
X	NULL
,	NULL
and	NULL
X	NULL
;	NULL
,	NULL
motifs	NULL
is	NULL
completely	NULL
protected	NULL
on	NULL
the	NULL
lower	NULL
strand	NULL
,	NULL
with	NULL
one	NULL
hypersensitive	NULL
site	NULL
at	NULL
the	NULL
3	NULL
'	NULL
end	NULL
.	NULL

The	NULL
upper	NULL
strand	NULL
also	NULL
reveals	NULL
protections	NULL
in	NULL
both	NULL
X	NULL
;	NULL
and	NULL
X	NULL
;	NULL
,	NULL
with	NULL
a	NULL
hypersensitive	NULL
site	NULL
between	NULL
the	NULL
two	NULL
motifs	NULL
at	NULL
-95	NULL
.	NULL

Interestingly	NULL
,	NULL
a	NULL
single	NULL
hypersensitive	NULL
adenosine	NULL
residue	NULL
appears	NULL
on	NULL
the	NULL
upper	NULL
strand	NULL
between	NULL
the	NULL
X	NULL
region	NULL
and	NULL
the	NULL
Y	NULL
box	NULL
when	NULL
protein	NULL
is	NULL
bound	NULL
to	NULL
these	NULL
elements	NULL
.	NULL

Adenosine	NULL
hypersensitivity	NULL
is	NULL
generated	NULL
by	NULL
an	NULL
increased	NULL
accessibility	NULL
of	NULL
dimethyl	NULL
sulfate	NULL
to	NULL
the	NULL
minor	NULL
grove	NULL
of	NULL
the	NULL
DNA	NULL
,	NULL
perhaps	NULL
due	NULL
to	NULL
a	NULL
distortion	NULL
in	NULL
the	NULL
three-dimensional	NULL
structure	NULL
.	NULL

Two	NULL
additional	NULL
hypersensitive	NULL
adenosine	NULL
residues	NULL
were	NULL
detected	NULL
upstream	NULL
of	NULL
the	NULL
X	NULL
region	NULL
on	NULL
the	NULL
upper	NULL
strand	NULL
(	NULL
-117	NULL
and	NULL
-150	NULL
)	NULL
.	NULL

These	NULL
contact	NULL
points	NULL
are	NULL
not	NULL
obviously	NULL
associated	NULL
with	NULL
any	NULL
currently	NULL
known	NULL
in	NULL
vitro	NULL
binding	NULL
sites	NULL
;	NULL
however	NULL
,	NULL
gross	NULL
deletion	NULL
of	NULL
the	NULL
region	NULL
diminishes	NULL
expression	NULL
in	NULL
B-LCLs	NULL
(	NULL
18	NULL
,	NULL
32	NULL
,	NULL
43	NULL
)	NULL
.	NULL

Class	NULL
II	NULL
Negative	NULL
T-LCLs	NULL
Lack	NULL
in	NULL
Vivo	NULL
Protein-DNA	NULL
Interactions	NULL
While	NULL
a	NULL
Class	NULL
II-Expressing	NULL
T-LCL	NULL
Is	NULL
Indistinguishable	NULL
from	NULL
B-LCLs	NULL
.	NULL

Human	NULL
T	NULL
lymphocytes	NULL
are	NULL
unique	NULL
in	NULL
their	NULL
ability	NULL
to	NULL
express	NULL
cell-surface	NULL
class	NULL
II	NULL
molecules	NULL
upon	NULL
antigen	NULL
or	NULL
mitogen	NULL
activation	NULL
(	NULL
10-12	NULL
)	NULL
or	NULL
human	NULL
T-lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
infection	NULL
(	NULL
44	NULL
)	NULL
.	NULL

We	NULL
examined	NULL
the	NULL
class	NULL
-expressing	NULL
T-LCL	NULL
H9	NULL
for	NULL
in	NULL
vivo	NULL
protein-DNA	NULL
interactions	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
DRA	NULL
promoter	NULL
revealed	NULL
guanine	NULL
contact	NULL
points	NULL
at	NULL
the	NULL
oc-tamer	NULL
,	NULL
Y	NULL
box	NULL
,	NULL
and	NULL
X	NULL
;	NULL
,	NULL
and	NULL
X	NULL
;	NULL
motifs	NULL
,	NULL
which	NULL
were	NULL
indistinguishable	NULL
from	NULL
the	NULL
contacts	NULL
detected	NULL
in	NULL
B-LCLs	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
in	NULL
human	NULL
B-LCLs	NULL
and	NULL
class	NULL
-expressing	NULL
T-LCLs	NULL
the	NULL
same	NULL
interactions	NULL
are	NULL
important	NULL
for	NULL
class	NULL
II	NULL
gene	NULL
expression	NULL
.	NULL

However	NULL
,	NULL
many	NULL
human	NULL
T-LCLs	NULL
are	NULL
class	NULL
II	NULL
negative	NULL
and	NULL
can	NULL
not	NULL
be	NULL
induced	NULL
to	NULL
express	NULL
class	NULL
II	NULL
antigens	NULL
.	NULL

Two	NULL
such	NULL
class	NULL
II-negative	NULL
T-LCLs-Jurkat	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
and	NULL
HSB	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
-exhibited	NULL
no	NULL
detectable	NULL
protein-DNA	NULL
interactions	NULL
at	NULL
the	NULL
DRA	NULL
promoter	NULL
.	NULL

Some	NULL
experiments	NULL
with	NULL
the	NULL
Jurkat	NULL
cell	NULL
line	NULL
suggested	NULL
a	NULL
weak	NULL
interaction	NULL
at	NULL
the	NULL
octamer	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
;	NULL
however	NULL
,	NULL
this	NULL
was	NULL
not	NULL
consistently	NULL
reproducible	NULL
.	NULL

This	NULL
result	NULL
is	NULL
in	NULL
stark	NULL
contrast	NULL
to	NULL
the	NULL
in	NULL
vitro	NULL
binding	NULL
studies	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
HSB	NULL
cells	NULL
(	NULL
19	NULL
)	NULL
,	NULL
where	NULL
DNA	NULL
probes	NULL
spanning	NULL
the	NULL
class	NULL
HI	NULL
box	NULL
reveal	NULL
specific	NULL
protein-DNA	NULL
interactions	NULL
that	NULL
are	NULL
qualitatively	NULL
indistinguishable	NULL
from	NULL
the	NULL
class	NULL
B-	NULL
or	NULL
T-LCLs	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
class	NULL
II-negative	NULL
human	NULL
T-LCLs	NULL
down-regulate	NULL
DRA	NULL
expression	NULL
not	NULL
at	NULL
the	NULL
level	NULL
of	NULL
individual	NULL
transcription	NULL
factors	NULL
but	NULL
rather	NULL
at	NULL
the	NULL
level	NULL
of	NULL
chromatin	NULL
structure	NULL
.	NULL

In	NULL
Vivo	NULL
Discrimination	NULL
Against	NULL
OTF-1	NULL
Binding	NULL
at	NULL
an	NULL
Available	NULL
Octamer	NULL
Consensus	NULL
Sequence	NULL
in	NULL
a	NULL
Functioning	NULL
DRA	NULL
Promoter	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
constitutive	NULL
mode	NULL
of	NULL
class	NULL
II	NULL
antigen	NULL
expression	NULL
,	NULL
several	NULL
cell	NULL
types	NULL
can	NULL
be	NULL
induced	NULL
to	NULL
express	NULL
class	NULL
II	NULL
by	NULL
treatment	NULL
with	NULL
cytokines	NULL
such	NULL
as	NULL
IFN-y	NULL
.	NULL

We	NULL
examined	NULL
the	NULL
human	NULL
glioblastoma	NULL
multiform	NULL
line	NULL
U373-MG	NULL
as	NULL
an	NULL
example	NULL
of	NULL
a	NULL
class	NULL
II-inducible	NULL
,	NULL
nonlymphoid	NULL
cell	NULL
(	NULL
15	NULL
)	NULL
.	NULL

The	NULL
U373-MG	NULL
cell	NULL
line	NULL
has	NULL
a	NULL
low	NULL
level	NULL
of	NULL
cell-surface	NULL
class	NULL
II-positive	NULL
cells	NULL
(	NULL
10-20	NULL
%	NULL
)	NULL
,	NULL
which	NULL
is	NULL
induced	NULL
to	NULL
high	NULL
levels	NULL
(	NULL
70	NULL
%	NULL
)	NULL
by	NULL
IFN-y	NULL
(	NULL
ref	NULL
.	NULL

15	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

A	NULL
striking	NULL
deviation	NULL
from	NULL
the	NULL
observations	NULL
in	NULL
class	NULL
II-positive	NULL
B-	NULL
and	NULL
T-LCLs	NULL
was	NULL
detected	NULL
at	NULL
the	NULL
octamer	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
7	NULL
vs.	NULL
lanes	NULL
11	NULL
and	NULL
12	NULL
)	NULL
.	NULL

No	NULL
protections	NULL
were	NULL
displayed	NULL
at	NULL
the	NULL
octamer	NULL
consensus	NULL
site	NULL
on	NULL
either	NULL
strand	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
octamer	NULL
site	NULL
remained	NULL
vacant	NULL
even	NULL
after	NULL
IFN-y	NULL
induction	NULL
of	NULL
DRA	NULL
transcription	NULL
at	NULL
18	NULL
and	NULL
24	NULL
hr	NULL
.	NULL

Identical	NULL
results	NULL
were	NULL
obtained	NULL
by	NULL
using	NULL
the	NULL
melanoma	NULL
cell	NULL
line	NULL
Thayer	NULL
,	NULL
which	NULL
is	NULL
only	NULL
1-2	NULL
%	NULL
cell-surface	NULL
class	NULL
II	NULL
positive	NULL
and	NULL
is	NULL
induced	NULL
to	NULL
80-85	NULL
%	NULL
by	NULL
IFN-y	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
prompted	NULL
us	NULL
to	NULL
examine	NULL
the	NULL
functional	NULL
requirement	NULL
of	NULL
this	NULL
site	NULL
and	NULL
the	NULL
availability	NULL
of	NULL
octamer	NULL
transcription	NULL
factors	NULL
.	NULL

Functional	NULL
importance	NULL
was	NULL
determined	NULL
by	NULL
transient	NULL
transfection	NULL
of	NULL
a	NULL
minimal	NULL
DRA	NULL
promoter	NULL
construct	NULL
containing	NULL
either	NULL
a	NULL
wild-type	NULL
or	NULL
a	NULL
mutated	NULL
octamer	NULL
site	NULL
in	NULL
the	NULL
context	NULL
of	NULL
S	NULL
,	NULL
X1	NULL
,	NULL
X	NULL
;	NULL
,	NULL
and	NULL
Y	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
(	NULL
1992	NULL
)	NULL
7603	NULL
UPPER	NULL
STRAND	NULL
LOWER	NULL
STRAND	NULL
Namalwa	NULL
Con	NULL
0	NULL
4	NULL
18	NULL
48hr	NULL
Con	NULL
O	NULL
4	NULL
18	NULL
48hr	NULL
Con	NULL
DMS	NULL
o	NULL
-	NULL
%	NULL
cose	NULL
oce	NULL
os	NULL
6	NULL
7ยฐ	NULL
6	NULL
9	NULL
``	NULL
ยฉ	NULL
I1	NULL
12	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
FiG	NULL
.	NULL

3	NULL
.	NULL

IFN-y	NULL
induction	NULL
of	NULL
class	NULL
II	NULL
expression	NULL
in	NULL
a	NULL
glioblastoma	NULL
cell	NULL
line	NULL
up-regulates	NULL
X	NULL
box	NULL
interactions	NULL
.	NULL

In	NULL
vivo	NULL
footprinting	NULL
of	NULL
the	NULL
upper	NULL
and	NULL
lower	NULL
strands	NULL
of	NULL
the	NULL
U373-MG	NULL
cell	NULL
line	NULL
was	NULL
as	NULL
indicated	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Con	NULL
,	NULL
in	NULL
vitro	NULL
methylated	NULL
deproteinized	NULL
DNA	NULL
.	NULL

Lanes	NULL
0	NULL
,	NULL
4	NULL
,	NULL
18	NULL
,	NULL
and	NULL
48	NULL
hr	NULL
,	NULL
in	NULL
vivo	NULL
methylated	NULL
DNA	NULL
harvested	NULL
at	NULL
the	NULL
time	NULL
indicated	NULL
after	NULL
addition	NULL
of	NULL
IFN-y	NULL
(	NULL
500	NULL
units/ml	NULL
)	NULL
.	NULL

Symbols	NULL
and	NULL
contact	NULL
points	NULL
are	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Namalwa	NULL
lower	NULL
strand	NULL
in	NULL
vivo	NULL
footprint	NULL
is	NULL
overexposed	NULL
to	NULL
reveal	NULL
complete	NULL
protection	NULL
of	NULL
the	NULL
X	NULL
box	NULL
region	NULL
as	NULL
compared	NULL
to	NULL
weak	NULL
X	NULL
box	NULL
protection	NULL
at	NULL
0	NULL
and	NULL
4	NULL
hr	NULL
post-IFN-y	NULL
induction	NULL
in	NULL
the	NULL
U373-MG	NULL
cell	NULL
line	NULL
.	NULL

Induced	NULL
U373-MG	NULL
cells	NULL
(	NULL
18	NULL
and	NULL
48	NULL
hr	NULL
)	NULL
were	NULL
indistinguishable	NULL
from	NULL
the	NULL
B-LCLs	NULL
except	NULL
for	NULL
the	NULL
lack	NULL
of	NULL
octamer	NULL
binding	NULL
.	NULL

sequences	NULL
.	NULL

The	NULL
results	NULL
confirmed	NULL
a	NULL
functional	NULL
requirement	NULL
of	NULL
the	NULL
octamer	NULL
site	NULL
in	NULL
Raji	NULL
B-LCL	NULL
and	NULL
in	NULL
H9	NULL
T-LCL	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
U373-MG	NULL
cells	NULL
mutation	NULL
of	NULL
the	NULL
octamer	NULL
site	NULL
did	NULL
not	NULL
result	NULL
in	NULL
a	NULL
loss	NULL
of	NULL
promoter	NULL
function	NULL
but	NULL
instead	NULL
caused	NULL
a	NULL
minimal	NULL
(	NULL
<	NULL
2-fold	NULL
)	NULL
increase	NULL
in	NULL
activity	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
functional	NULL
importance	NULL
of	NULL
the	NULL
octamer	NULL
site	NULL
parallels	NULL
its	NULL
in	NULL
vivo	NULL
occupancy	NULL
.	NULL

A	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
(	NULL
OTF	NULL
)	NULL
has	NULL
been	NULL
identified	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
octamer	NULL
consensus	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
Raji	NULL
,	NULL
H9	NULL
,	NULL
and	NULL
U373-MG	NULL
cells	NULL
were	NULL
subjected	NULL
to	NULL
a	NULL
gel	NULL
mobility-shift	NULL
assay	NULL
with	NULL
a	NULL
DRA	NULL
octamer	NULL
probe	NULL
to	NULL
resolve	NULL
the	NULL
OTF	NULL
family	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

The	NULL
most	NULL
intense	NULL
band	NULL
(	NULL
band	NULL
A	NULL
)	NULL
corresponds	NULL
to	NULL
the	NULL
ubiquitous	NULL
OTF-1	NULL
factor	NULL
,	NULL
according	NULL
to	NULL
Gerster	NULL
et	NULL
al	NULL
.	NULL

(	NULL
40	NULL
)	NULL
,	NULL
and	NULL
is	NULL
present	NULL
in	NULL
each	NULL
cell	NULL
line	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
lack	NULL
of	NULL
in	NULL
vivo	NULL
binding	NULL
in	NULL
the	NULL
U373-MG	NULL
cells	NULL
suggests	NULL
that	NULL
OTF-1	NULL
is	NULL
discriminated	NULL
against	NULL
by	NULL
the	NULL
endogenous	NULL
DRA	NULL
promoter	NULL
structure	NULL
in	NULL
this	NULL
cell	NULL
line	NULL
.	NULL

A	NULL
second	NULL
band	NULL
(	NULL
band	NULL
B	NULL
)	NULL
,	NULL
most	NULL
likely	NULL
representing	NULL
the	NULL
lymphoid-specific	NULL
OTF-2	NULL
factor	NULL
,	NULL
is	NULL
present	NULL
at	NULL
high	NULL
levels	NULL
in	NULL
Raji	NULL
cells	NULL
.	NULL

Interestingly	NULL
,	NULL
in	NULL
H9	NULL
nuclear	NULL
extracts	NULL
a	NULL
weak	NULL
but	NULL
detectable	NULL
complex	NULL
comigrates	NULL
with	NULL
this	NULL
band	NULL
(	NULL
band	NULL
B	NULL
)	NULL
.	NULL

However	NULL
,	NULL
this	NULL
band	NULL
is	NULL
absent	NULL
in	NULL
the	NULL
U373-MG	NULL
cell	NULL
extracts	NULL
.	NULL

The	NULL
availability	NULL
of	NULL
this	NULL
factor	NULL
directly	NULL
corre-	NULL
Table	NULL
1	NULL
.	NULL

Functional	NULL
analysis	NULL
of	NULL
the	NULL
DRA	NULL
octamer	NULL
site	NULL
Relative	NULL
CAT	NULL
Cell	NULL
type	NULL
Plasmid	NULL
activity	NULL
Raji	NULL
5	NULL
'	NULL
A-152	NULL
WT	NULL
1.00	NULL
(	NULL
3.8	NULL
%	NULL
)	NULL
5	NULL
'	NULL
A-152	NULL
MUTocta	NULL
0.30	NULL
+	NULL
0.06	NULL
H9	NULL
5	NULL
'	NULL
A-152	NULL
WT	NULL
1.00	NULL
(	NULL
1.3	NULL
%	NULL
)	NULL
5	NULL
'	NULL
A-152	NULL
MUTocta	NULL
0.16	NULL
+	NULL
0.12	NULL
U373-MG	NULL
5	NULL
'	NULL
A-152	NULL
WT	NULL
1.00	NULL
(	NULL
1.7	NULL
%	NULL
)	NULL
5	NULL
'	NULL
A-152	NULL
MUTocta	NULL
1.70	NULL
+	NULL
0.01	NULL
Test	NULL
plasmids	NULL
contain	NULL
the	NULL
DRA	NULL
promoter	NULL
sequences	NULL
up	NULL
to	NULL
-152	NULL
fused	NULL
to	NULL
the	NULL
CAT	NULL
reporter	NULL
gene	NULL
.	NULL

Relative	NULL
CAT	NULL
activity	NULL
is	NULL
normalized	NULL
within	NULL
each	NULL
cell	NULL
line	NULL
to	NULL
the	NULL
5	NULL
'	NULL
A-152	NULL
WT	NULL
construct	NULL
and	NULL
average	NULL
percentage	NULL
acetylation	NULL
is	NULL
given	NULL
in	NULL
parentheses	NULL
.	NULL

U373-MG	NULL
expression	NULL
was	NULL
assayed	NULL
48	NULL
hr	NULL
after	NULL
IFN-y	NULL
induction	NULL
.	NULL

Values	NULL
represent	NULL
average	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
and	NULL
Raji	NULL
and	NULL
U373-MG	NULL
results	NULL
confirm	NULL
our	NULL
previous	NULL
findings	NULL
(	NULL
29	NULL
)	NULL
.	NULL

7604	NULL
Biochemistry	NULL
:	NULL
Wright	NULL
and	NULL
Ting	NULL
Raji	NULL
H9	NULL
U373-MG	NULL
1	NULL
2.3	NULL
4.5.6.7	NULL
8	NULL
.	NULL

9	NULL
10.1112	NULL
is	NULL
eviey	NULL
is	NULL
as	NULL
i	NULL
an	NULL
~~	NULL
wag	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

-	NULL
Gel	NULL
mobility-shift	NULL
assay	NULL
reveals	NULL
a	NULL
family	NULL
of	NULL
OTF	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
DRA	NULL
octamer	NULL
site	NULL
.	NULL

Source	NULL
of	NULL
the	NULL
nuclear	NULL
extract	NULL
is	NULL
indicated	NULL
above	NULL
each	NULL
set	NULL
of	NULL
four	NULL
lanes	NULL
,	NULL
which	NULL
represent	NULL
increasing	NULL
amounts	NULL
of	NULL
nuclear	NULL
extract	NULL
from	NULL
3	NULL
to	NULL
12	NULL
ug	NULL
.	NULL

Band	NULL
A	NULL
represents	NULL
the	NULL
OTF-1	NULL
complex	NULL
,	NULL
which	NULL
is	NULL
present	NULL
in	NULL
all	NULL
three	NULL
extracts	NULL
.	NULL

Band	NULL
B	NULL
represents	NULL
complexes	NULL
comigrating	NULL
with	NULL
OTF-2	NULL
and	NULL
is	NULL
present	NULL
in	NULL
Raji	NULL
extracts	NULL
and	NULL
weakly	NULL
in	NULL
H9	NULL
extracts	NULL
.	NULL

Band	NULL
B	NULL
is	NULL
absent	NULL
in	NULL
the	NULL
U373-MG	NULL
extract	NULL
.	NULL

Bands	NULL
A	NULL
and	NULL
B	NULL
can	NULL
be	NULL
blocked	NULL
by	NULL
competition	NULL
with	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
octamer	NULL
motif	NULL
(	NULL
ref	NULL
.	NULL

29	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Bands	NULL
C	NULL
and	NULL
D	NULL
are	NULL
nonspecific	NULL
and	NULL
consistent	NULL
across	NULL
all	NULL
of	NULL
the	NULL
extracts	NULL
.	NULL

sponds	NULL
to	NULL
the	NULL
in	NULL
vivo	NULL
occupancy	NULL
of	NULL
the	NULL
octamer	NULL
site	NULL
and	NULL
provides	NULL
further	NULL
credence	NULL
implicating	NULL
OTF-2	NULL
as	NULL
the	NULL
functional	NULL
factor	NULL
activating	NULL
DRA	NULL
transcription	NULL
.	NULL

IFN-y	NULL
Induction	NULL
of	NULL
Class	NULL
II	NULL
Expression	NULL
in	NULL
a	NULL
Glioblastoma	NULL
Cell	NULL
Line	NULL
Is	NULL
Paralleled	NULL
by	NULL
an	NULL
Up-Regulation	NULL
of	NULL
in	NULL
Vivo	NULL
Binding	NULL
at	NULL
the	NULL
X	NULL
,	NULL
and	NULL
X	NULL
,	NULL
Boxes	NULL
.	NULL

Before	NULL
IFN-y	NULL
induction	NULL
,	NULL
a	NULL
second	NULL
distinction	NULL
was	NULL
observed	NULL
between	NULL
B-LCLs	NULL
and	NULL
the	NULL
U373-MG	NULL
cell	NULL
line	NULL
.	NULL

The	NULL
guanine	NULL
residues	NULL
within	NULL
the	NULL
X	NULL
;	NULL
,	NULL
and	NULL
X	NULL
;	NULL
,	NULL
motifs	NULL
were	NULL
partially	NULL
visible	NULL
in	NULL
the	NULL
in	NULL
vivo	NULL
0-hr	NULL
sample	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

This	NULL
is	NULL
most	NULL
clearly	NULL
revealed	NULL
on	NULL
the	NULL
lower	NULL
strand	NULL
.	NULL

The	NULL
intensity	NULL
of	NULL
the	NULL
X	NULL
region	NULL
guanine	NULL
bands	NULL
is	NULL
only	NULL
reduced	NULL
by	NULL
=60	NULL
%	NULL
compared	NULL
to	NULL
the	NULL
deproteinized	NULL
control	NULL
DNA	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
the	NULL
B-LCLs	NULL
there	NULL
was	NULL
a	NULL
complete	NULL
protection	NULL
of	NULL
the	NULL
X	NULL
;	NULL
and	NULL
X	NULL
,	NULL
regions	NULL
.	NULL

Contact	NULL
points	NULL
in	NULL
the	NULL
Y	NULL
box	NULL
and	NULL
upstream	NULL
region	NULL
were	NULL
similar	NULL
between	NULL
the	NULL
lymphoid	NULL
and	NULL
glioblastoma	NULL
cell	NULL
lines	NULL
.	NULL

IFN-y	NULL
treatment	NULL
of	NULL
the	NULL
U373-MG	NULL
cell	NULL
line	NULL
induces	NULL
a	NULL
peak	NULL
of	NULL
mRNA	NULL
accumulation	NULL
at	NULL
18-24	NULL
hr	NULL
,	NULL
which	NULL
is	NULL
primarily	NULL
controlled	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
(	NULL
46	NULL
,	NULL
47	NULL
)	NULL
.	NULL

At	NULL
4	NULL
hr	NULL
,	NULL
no	NULL
changes	NULL
in	NULL
the	NULL
in	NULL
vivo	NULL
footprint	NULL
are	NULL
observed	NULL
.	NULL

However	NULL
,	NULL
concomitant	NULL
with	NULL
the	NULL
up-regulation	NULL
of	NULL
class	NULL
II	NULL
transcription	NULL
,	NULL
the	NULL
in	NULL
vivo	NULL
footprint	NULL
of	NULL
the	NULL
X	NULL
region	NULL
at	NULL
18	NULL
and	NULL
48	NULL
hr	NULL
revealed	NULL
a	NULL
change	NULL
to	NULL
complete	NULL
protection	NULL
of	NULL
all	NULL
of	NULL
the	NULL
X	NULL
region	NULL
guanine	NULL
residues	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

The	NULL
up-regulation	NULL
of	NULL
in	NULL
vivo	NULL
interaction	NULL
at	NULL
the	NULL
X	NULL
region	NULL
makes	NULL
this	NULL
region	NULL
indistinguishable	NULL
from	NULL
the	NULL
class	NULL
-expressing	NULL
lymphoid	NULL
cell	NULL
lines	NULL
.	NULL

DISCUSSION	NULL
Myriad	NULL
in	NULL
vitro	NULL
protein-DNA	NULL
binding	NULL
events	NULL
have	NULL
been	NULL
ascribed	NULL
to	NULL
the	NULL
DRA	NULL
promoter	NULL
regions	NULL
.	NULL

However	NULL
,	NULL
it	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
whether	NULL
the	NULL
in	NULL
vitro	NULL
studies	NULL
accurately	NULL
reflect	NULL
conditions	NULL
in	NULL
the	NULL
intact	NULL
cell	NULL
.	NULL

The	NULL
analysis	NULL
described	NULL
here	NULL
provides	NULL
important	NULL
insight	NULL
into	NULL
the	NULL
in	NULL
vivo	NULL
state	NULL
of	NULL
protein-DNA	NULL
interactions	NULL
at	NULL
the	NULL
DRA	NULL
promoter	NULL
.	NULL

B	NULL
cells	NULL
constitutively	NULL
express	NULL
class	NULL
II	NULL
and	NULL
were	NULL
used	NULL
to	NULL
define	NULL
a	NULL
reference	NULL
panel	NULL
of	NULL
in	NULL
vivo	NULL
protein-DNA	NULL
interactions	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

The	NULL
data	NULL
obtained	NULL
with	NULL
B	NULL
cells	NULL
in	NULL
this	NULL
report	NULL
confirm	NULL
the	NULL
initial	NULL
findings	NULL
on	NULL
the	NULL
upper	NULL
strand	NULL
of	NULL
the	NULL
DRA	NULL
promoter	NULL
by	NULL
Kara	NULL
and	NULL
Glimcher	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Their	NULL
results	NULL
with	NULL
the	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
(	NULL
1992	NULL
)	NULL
DRA	NULL
gene	NULL
identified	NULL
promoter	NULL
interactions	NULL
at	NULL
the	NULL
octamer	NULL
site	NULL
and	NULL
the	NULL
Y	NULL
,	NULL
X1	NULL
,	NULL
and	NULL
X	NULL
;	NULL
boxes	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
they	NULL
found	NULL
a	NULL
lack	NULL
of	NULL
all	NULL
interactions	NULL
in	NULL
class	NULL
II-deficient	NULL
mutant	NULL
cell	NULL
lines	NULL
derived	NULL
from	NULL
certain	NULL
bare	NULL
lymphocyte	NULL
syndrome	NULL
patients	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
have	NULL
extensively	NULL
expanded	NULL
these	NULL
initial	NULL
studies	NULL
in	NULL
B-cell	NULL
lines	NULL
to	NULL
include	NULL
class	NULL
II-positive	NULL
and	NULL
-negative	NULL
T-cell	NULL
lines	NULL
and	NULL
an	NULL
IFN-y	NULL
inducible	NULL
,	NULL
nonlymphoblastoid	NULL
cell	NULL
line	NULL
.	NULL

In	NULL
B-LCLs	NULL
and	NULL
a	NULL
class	NULL
II-positive	NULL
T-LCL	NULL
,	NULL
the	NULL
octamer	NULL
site	NULL
was	NULL
occupied	NULL
.	NULL

This	NULL
occupancy	NULL
is	NULL
most	NULL
likely	NULL
associated	NULL
with	NULL
the	NULL
presence	NULL
of	NULL
OTF-2	NULL
in	NULL
lymphoid	NULL
cells	NULL
,	NULL
although	NULL
the	NULL
possibility	NULL
that	NULL
OTF-1	NULL
occupies	NULL
this	NULL
site	NULL
in	NULL
conjunction	NULL
with	NULL
other	NULL
lymphoid-specific	NULL
factors	NULL
can	NULL
not	NULL
be	NULL
excluded	NULL
at	NULL
this	NULL
time	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
octamer	NULL
site	NULL
was	NULL
vacant	NULL
in	NULL
the	NULL
non-lymphoid	NULL
,	NULL
glioblastoma	NULL
cell	NULL
line	NULL
.	NULL

This	NULL
finding	NULL
agrees	NULL
with	NULL
the	NULL
functional	NULL
analysis	NULL
showing	NULL
a	NULL
requirement	NULL
for	NULL
these	NULL
sequences	NULL
in	NULL
B-LCLs	NULL
and	NULL
a	NULL
class	NULL
II-positive	NULL
T-LCL	NULL
but	NULL
not	NULL
in	NULL
the	NULL
glioblastoma	NULL
cells	NULL
(	NULL
Table	NULL
1	NULL
and	NULL
ref	NULL
.	NULL

29	NULL
)	NULL
.	NULL

The	NULL
slight	NULL
increase	NULL
in	NULL
activity	NULL
seen	NULL
in	NULL
the	NULL
glioblastoma	NULL
cells	NULL
upon	NULL
mutation	NULL
of	NULL
the	NULL
octamer	NULL
site	NULL
may	NULL
suggest	NULL
an	NULL
uncharacterized	NULL
repressive	NULL
role	NULL
for	NULL
this	NULL
site	NULL
in	NULL
nonlymphoid	NULL
class	NULL
II-positive	NULL
cells	NULL
.	NULL

The	NULL
apparent	NULL
vacancy	NULL
of	NULL
the	NULL
octamer	NULL
site	NULL
in	NULL
the	NULL
glioblastoma	NULL
cell	NULL
occurs	NULL
despite	NULL
the	NULL
availability	NULL
of	NULL
the	NULL
ubiquitous	NULL
OTF-1	NULL
factor	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
lack	NULL
of	NULL
octamer	NULL
binding	NULL
is	NULL
apparently	NULL
not	NULL
due	NULL
to	NULL
differences	NULL
in	NULL
the	NULL
adjacent	NULL
interactions	NULL
,	NULL
since	NULL
all	NULL
of	NULL
the	NULL
neighboring	NULL
contact	NULL
points	NULL
are	NULL
the	NULL
same	NULL
between	NULL
the	NULL
lymphoid	NULL
and	NULL
nonlymphoid	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
provide	NULL
the	NULL
first	NULL
direct	NULL
evidence	NULL
that	NULL
in	NULL
vivo	NULL
the	NULL
OTF-1	NULL
binding	NULL
interaction	NULL
is	NULL
selectively	NULL
excluded	NULL
in	NULL
a	NULL
functional	NULL
promoter	NULL
.	NULL

One	NULL
explanation	NULL
for	NULL
the	NULL
exclusion	NULL
may	NULL
be	NULL
inappropriate	NULL
contacts	NULL
between	NULL
OTF-1	NULL
and	NULL
the	NULL
other	NULL
transacting	NULL
factors	NULL
present	NULL
on	NULL
the	NULL
promoter	NULL
in	NULL
this	NULL
cell	NULL
line	NULL
.	NULL

At	NULL
present	NULL
,	NULL
it	NULL
is	NULL
unclear	NULL
whether	NULL
the	NULL
exclusion	NULL
of	NULL
octamer	NULL
occupancy	NULL
is	NULL
unique	NULL
to	NULL
the	NULL
glioblastoma	NULL
cell	NULL
line	NULL
or	NULL
is	NULL
common	NULL
to	NULL
all	NULL
nonlymphoid	NULL
class	NULL
II-positive	NULL
cells	NULL
.	NULL

The	NULL
in	NULL
vivo	NULL
protein-DNA	NULL
interactions	NULL
at	NULL
the	NULL
Y	NULL
box	NULL
and	NULL
the	NULL
X	NULL
;	NULL
and	NULL
X	NULL
;	NULL
boxes	NULL
confirm	NULL
the	NULL
functional	NULL
data	NULL
defining	NULL
each	NULL
of	NULL
these	NULL
elements	NULL
as	NULL
required	NULL
for	NULL
optimal	NULL
class	NULL
II	NULL
expression	NULL
.	NULL

In	NULL
B-LCLs	NULL
and	NULL
class	NULL
II-positive	NULL
T-LCLs	NULL
,	NULL
the	NULL
X	NULL
boxes	NULL
were	NULL
extensively	NULL
protected	NULL
.	NULL

The	NULL
contact	NULL
points	NULL
are	NULL
clustered	NULL
into	NULL
two	NULL
groups	NULL
.	NULL

One	NULL
group	NULL
lies	NULL
within	NULL
the	NULL
X	NULL
;	NULL
motif	NULL
with	NULL
single	NULL
hypersensitive	NULL
guanine	NULL
residues	NULL
immediately	NULL
flanking	NULL
each	NULL
side	NULL
of	NULL
the	NULL
X	NULL
;	NULL
box	NULL
,	NULL
suggesting	NULL
these	NULL
may	NULL
be	NULL
the	NULL
boundaries	NULL
of	NULL
the	NULL
X	NULL
;	NULL
interaction	NULL
.	NULL

The	NULL
second	NULL
cluster	NULL
lies	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
X	NULL
,	NULL
box	NULL
corresponding	NULL
to	NULL
the	NULL
putative	NULL
RF-X	NULL
interaction	NULL
domain	NULL
.	NULL

A	NULL
single	NULL
unprotected	NULL
guanine	NULL
residue	NULL
between	NULL
the	NULL
two	NULL
groups	NULL
suggests	NULL
that	NULL
the	NULL
X	NULL
;	NULL
and	NULL
X	NULL
;	NULL
boxes	NULL
are	NULL
separate	NULL
and	NULL
distinct	NULL
binding	NULL
events	NULL
.	NULL

The	NULL
hypersensitive	NULL
adenosine	NULL
residue	NULL
appearing	NULL
approximately	NULL
midway	NULL
between	NULL
the	NULL
X	NULL
and	NULL
the	NULL
Y	NULL
boxes	NULL
suggests	NULL
that	NULL
this	NULL
region	NULL
of	NULL
the	NULL
DNA	NULL
structure	NULL
may	NULL
be	NULL
distorted-for	NULL
example	NULL
,	NULL
by	NULL
DNA	NULL
bending	NULL
.	NULL

This	NULL
is	NULL
compatible	NULL
with	NULL
a	NULL
previous	NULL
study	NULL
,	NULL
which	NULL
demonstrated	NULL
a	NULL
functional	NULL
requirement	NULL
for	NULL
the	NULL
stereospecific	NULL
alignment	NULL
of	NULL
the	NULL
X	NULL
and	NULL
Y	NULL
boxes	NULL
that	NULL
was	NULL
independent	NULL
of	NULL
the	NULL
absolute	NULL
distance	NULL
between	NULL
the	NULL
two	NULL
domains	NULL
(	NULL
48	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
the	NULL
X	NULL
and	NULL
Y	NULL
box	NULL
factors	NULL
are	NULL
able	NULL
to	NULL
bend	NULL
the	NULL
intervening	NULL
DNA	NULL
to	NULL
come	NULL
in	NULL
direct	NULL
or	NULL
indirect	NULL
contact	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
hypersensitivity	NULL
occurs	NULL
only	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
X	NULL
and	NULL
Y	NULL
box	NULL
protein-DNA	NULL
interactions	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
putative	NULL
DNA	NULL
bend	NULL
may	NULL
be	NULL
driven	NULL
by	NULL
the	NULL
protein-protein	NULL
contacts	NULL
or	NULL
,	NULL
alternatively	NULL
,	NULL
by	NULL
protein-DNA	NULL
contacts	NULL
.	NULL

The	NULL
glioblastoma	NULL
cell	NULL
line	NULL
U373-MG	NULL
can	NULL
be	NULL
induced	NULL
by	NULL
IFN-y	NULL
to	NULL
express	NULL
high	NULL
levels	NULL
of	NULL
class	NULL
II	NULL
(	NULL
15	NULL
,	NULL
32	NULL
)	NULL
.	NULL

Before	NULL
IFN-y	NULL
induction	NULL
,	NULL
the	NULL
interactions	NULL
at	NULL
the	NULL
X	NULL
;	NULL
and	NULL
X	NULL
;	NULL
boxes	NULL
are	NULL
weak	NULL
compared	NULL
to	NULL
B-LCLs	NULL
.	NULL

Concomitant	NULL
with	NULL
the	NULL
induction	NULL
of	NULL
DRA	NULL
transcription	NULL
,	NULL
the	NULL
X	NULL
box	NULL
interactions	NULL
increase	NULL
in	NULL
intensity	NULL
to	NULL
levels	NULL
indistinguishable	NULL
from	NULL
B	NULL
cells	NULL
.	NULL

No	NULL
other	NULL
changes	NULL
are	NULL
detected	NULL
during	NULL
the	NULL
induction	NULL
.	NULL

Identical	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
the	NULL
melanoma	NULL
cell	NULL
line	NULL
Thayer	NULL
,	NULL
which	NULL
are	NULL
induced	NULL
to	NULL
~80	NULL
%	NULL
class	NULL
II-positive	NULL
by	NULL
IFN-y	NULL
.	NULL

These	NULL
results	NULL
Biochemistry	NULL
:	NULL
Wright	NULL
and	NULL
Ting	NULL
indicate	NULL
that	NULL
in	NULL
an	NULL
inducible	NULL
cell	NULL
the	NULL
DRA	NULL
gene	NULL
is	NULL
poised	NULL
for	NULL
expression	NULL
with	NULL
the	NULL
majority	NULL
of	NULL
protein-DNA	NULL
interactions	NULL
in	NULL
place	NULL
.	NULL

However	NULL
,	NULL
the	NULL
X	NULL
box	NULL
interactions	NULL
are	NULL
weak	NULL
and	NULL
potentially	NULL
nonproductive	NULL
.	NULL

IFN-y	NULL
may	NULL
induce	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
existing	NULL
X	NULL
box	NULL
interactions	NULL
to	NULL
make	NULL
the	NULL
binding	NULL
productive	NULL
or	NULL
,	NULL
alternatively	NULL
,	NULL
induce	NULL
new	NULL
protein-DNA	NULL
interactions	NULL
.	NULL

Recent	NULL
results	NULL
have	NULL
confirmed	NULL
an	NULL
increase	NULL
in	NULL
X	NULL
box	NULL
binding	NULL
in	NULL
vitro	NULL
in	NULL
primary	NULL
rat	NULL
astrocytes	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
no	NULL
contact	NULL
points	NULL
directly	NULL
attributable	NULL
to	NULL
the	NULL
S	NULL
site	NULL
were	NULL
detected	NULL
.	NULL

Functional	NULL
analysis	NULL
of	NULL
the	NULL
IFN-y	NULL
induction	NULL
has	NULL
demonstrated	NULL
a	NULL
requirement	NULL
for	NULL
the	NULL
S	NULL
site	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
S	NULL
interaction	NULL
escapes	NULL
detection	NULL
by	NULL
the	NULL
in	NULL
vivo	NULL
footprinting	NULL
tech-nique	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
S	NULL
domain	NULL
may	NULL
be	NULL
the	NULL
site	NULL
of	NULL
a	NULL
transient	NULL
binding	NULL
activity	NULL
only	NULL
required	NULL
in	NULL
the	NULL
initial	NULL
stages	NULL
of	NULL
the	NULL
IFN-y	NULL
response	NULL
.	NULL

A	NULL
transient	NULL
interaction	NULL
has	NULL
been	NULL
recently	NULL
demonstrated	NULL
for	NULL
the	NULL
overlapping	NULL
IFN-a/y	NULL
response	NULL
site	NULL
in	NULL
the	NULL
gene	NULL
of	NULL
the	NULL
guanylate-binding	NULL
protein	NULL
(	NULL
49	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
poised	NULL
promoter	NULL
detected	NULL
in	NULL
the	NULL
glioblastoma	NULL
cell	NULL
line	NULL
prior	NULL
to	NULL
induction	NULL
,	NULL
the	NULL
class	NULL
II-negative	NULL
T-LCLs	NULL
displayed	NULL
no	NULL
protein-DNA	NULL
interactions	NULL
.	NULL

Class	NULL
II-negative	NULL
T-LCLs	NULL
can	NULL
not	NULL
be	NULL
induced	NULL
to	NULL
express	NULL
DRA	NULL
and	NULL
thus	NULL
do	NULL
not	NULL
maintain	NULL
a	NULL
poised	NULL
promoter	NULL
.	NULL

Down-regulation	NULL
of	NULL
transcription	NULL
through	NULL
prevention	NULL
of	NULL
all	NULL
interactions	NULL
at	NULL
the	NULL
promoter	NULL
,	NULL
perhaps	NULL
by	NULL
reordering	NULL
the	NULL
chromatin	NULL
structure	NULL
,	NULL
would	NULL
be	NULL
an	NULL
effective	NULL
mechanism	NULL
to	NULL
down-regulate	NULL
the	NULL
entire	NULL
class	NULL
II	NULL
locus	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
B-	NULL
and	NULL
T-lymphoid	NULL
cells	NULL
expressing	NULL
the	NULL
class	NULL
II	NULL
DRA	NULL
gene	NULL
,	NULL
maintain	NULL
constitutive	NULL
protein-DNA	NULL
interactions	NULL
at	NULL
the	NULL
octamer	NULL
site	NULL
and	NULL
the	NULL
Y	NULL
,	NULL
X1	NULL
,	NULL
and	NULL
X	NULL
,	NULL
boxes	NULL
.	NULL

However	NULL
,	NULL
the	NULL
octamer	NULL
site	NULL
is	NULL
not	NULL
occupied	NULL
in	NULL
the	NULL
nonlymphoid	NULL
cell	NULL
line	NULL
in	NULL
congruence	NULL
with	NULL
lymphoid-specific	NULL
function	NULL
of	NULL
this	NULL
site	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
there	NULL
is	NULL
a	NULL
dynamic	NULL
up-regulation	NULL
of	NULL
X	NULL
box	NULL
binding	NULL
in	NULL
parallel	NULL
with	NULL
the	NULL
induction	NULL
of	NULL
expression	NULL
by	NULL
IFN-y	NULL
in	NULL
class	NULL
II-inducible	NULL
cell	NULL
lines	NULL
.	NULL

The	NULL
authors	NULL
wish	NULL
to	NULL
thank	NULL
Dr.	NULL
Donald	NULL
Pious	NULL
for	NULL
the	NULL
generous	NULL
gift	NULL
of	NULL
the	NULL
melanoma	NULL
cell	NULL
line	NULL
Thayer	NULL
and	NULL
Drs	NULL
.	NULL

Anup	NULL
Dey	NULL
and	NULL
Keiko	NULL
Ozato	NULL
for	NULL
technical	NULL
advice	NULL
with	NULL
the	NULL
footprinting	NULL
procedure	NULL
.	NULL

The	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
CA48185	NULL
and	NULL
Al29564	NULL
and	NULL
by	NULL
National	NULL
Multiple	NULL
Sclerosis	NULL
Society	NULL
Grant	NULL
RG-185	NULL
.	NULL

J.P.-Y.T	NULL
.	NULL

is	NULL
the	NULL
recipient	NULL
of	NULL
an	NULL
American	NULL
Cancer	NULL
Society	NULL
Faculty	NULL
Award	NULL
.	NULL

K.L.W	NULL
.	NULL

is	NULL
a	NULL
recipient	NULL
of	NULL
a	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
training	NULL
grant	NULL
and	NULL
an	NULL
Arthritis	NULL
Foundation	NULL
Postdoctoral	NULL
Fellowship	NULL
.	NULL

1	NULL
.	NULL

Kaufman	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Auffray	NULL
,	NULL
C.	NULL
,	NULL
Korman	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Shackelford	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Strominger	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Cell	NULL
36	NULL
,	NULL
1-13	NULL
.	NULL

2	NULL
.	NULL

Cresswell	NULL
,	NULL
P.	NULL
(	NULL
1990	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
343	NULL
,	NULL
593-594	NULL
.	NULL

3	NULL
.	NULL

Lechler	NULL
,	NULL
R.	NULL
I.	NULL
,	NULL
Norcross	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

&	NULL
Germain	NULL
,	NULL
R.	NULL
N.	NULL
(	NULL
1985	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

135	NULL
,	NULL
2914-2922	NULL
.	NULL

4	NULL
.	NULL

Matis	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Jones	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Murphy	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
Hedrick	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Lerner	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Janeway	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Jr.	NULL
,	NULL
McNicholas	NULL
,	NULL
J.	NULL
M.	NULL
&	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1982	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

155	NULL
,	NULL
508-523	NULL
.	NULL

5	NULL
.	NULL

Nepom	NULL
,	NULL
G.	NULL
T.	NULL
&	NULL
Erlich	NULL
,	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

9	NULL
,	NULL
493-525	NULL
.	NULL

6	NULL
.	NULL

-	NULL
Hammerling	NULL
,	NULL
G.	NULL
J	NULL
.	NULL

(	NULL
1976	NULL
)	NULL
Transplant	NULL
.	NULL

Rev	NULL
.	NULL

30	NULL
,	NULL
64-82	NULL
.	NULL

7	NULL
.	NULL

-	NULL
Sasaki	NULL
,	NULL
A.	NULL
,	NULL
Levison	NULL
,	NULL
S.	NULL
W.	NULL
&	NULL
Ting	NULL
,	NULL
J.	NULL
P.-Y	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J.	NULL
Newroim-munol	NULL
.	NULL

25	NULL
,	NULL
63-74	NULL
.	NULL

8	NULL
.	NULL

Nixon	NULL
,	NULL
D.	NULL
F.	NULL
,	NULL
Ting	NULL
,	NULL
J.	NULL
P.-Y	NULL
.	NULL

&	NULL
Frelinger	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
3	NULL
,	NULL
339-342	NULL
.	NULL

9	NULL
.	NULL

Unanue	NULL
,	NULL
E.	NULL
R.	NULL
(	NULL
1981	NULL
)	NULL
Adv	NULL
.	NULL

Immunol	NULL
.	NULL

31	NULL
,	NULL
1-136	NULL
.	NULL

10	NULL
.	NULL

Charron	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Engleman	NULL
,	NULL
E.	NULL
G.	NULL
,	NULL
Benike	NULL
,	NULL
C.	NULL
J	NULL
.	NULL

&	NULL
McDevitt	NULL
,	NULL
H.	NULL
O	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

152	NULL
,	NULL
127s-136s	NULL
.	NULL

11	NULL
.	NULL

Cotner	NULL
,	NULL
T.	NULL
,	NULL
Williams	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Christenson	NULL
,	NULL
L.	NULL
,	NULL
Shapiro	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
Strom	NULL
,	NULL
T.	NULL
&	NULL
Strominger	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

157	NULL
,	NULL
461-472	NULL
.	NULL

12	NULL
.	NULL

Indiviri	NULL
,	NULL
F.	NULL
,	NULL
Wilson	NULL
,	NULL
B.	NULL
S.	NULL
,	NULL
Russo	NULL
,	NULL
C.	NULL
,	NULL
Quaranta	NULL
,	NULL
V.	NULL
,	NULL
Pellegrino	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

&	NULL
Ferrone	NULL
,	NULL
S.	NULL
(	NULL
1980	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

125	NULL
,	NULL
2673-2678	NULL
.	NULL

13	NULL
.	NULL

Pober	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Collins	NULL
,	NULL
T.	NULL
,	NULL
Gimbrone	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Cotran	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
Gitlin	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Fiers	NULL
,	NULL
W.	NULL
,	NULL
Clayberger	NULL
,	NULL
C.	NULL
,	NULL
Krensky	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Burakoff	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

&	NULL
Reiss	NULL
,	NULL
C.	NULL
S.	NULL
(	NULL
1983	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
305	NULL
,	NULL
726-1729	NULL
.	NULL

14	NULL
.	NULL

Houghton	NULL
,	NULL
A.	NULL
N.	NULL
,	NULL
Thomson	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Gross	NULL
,	NULL
D.	NULL
,	NULL
Oettgen	NULL
,	NULL
H.	NULL
F.	NULL
&	NULL
Old	NULL
,	NULL
L.	NULL
J	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

160	NULL
,	NULL
255-269	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

47	NULL
.	NULL

49	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
(	NULL
1992	NULL
)	NULL
7605	NULL
Takiguchi	NULL
,	NULL
M.	NULL
,	NULL
Ting	NULL
,	NULL
J	NULL
.	NULL

P.-Y	NULL
.	NULL

,	NULL
Buesow	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Boyer	NULL
,	NULL
C.	NULL
,	NULL
Gillespie	NULL
,	NULL
Y	NULL
.	NULL

&	NULL
Frelinger	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

15	NULL
,	NULL
809-814	NULL
.	NULL

Sasaki	NULL
,	NULL
A.	NULL
,	NULL
Levinson	NULL
,	NULL
S.	NULL
W.	NULL
&	NULL
Ting	NULL
,	NULL
J.	NULL
P.-Y	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
New-roimmunol	NULL
.	NULL

29	NULL
,	NULL
213-222	NULL
.	NULL

Cogswell	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Zeleznik-Le	NULL
,	NULL
N.	NULL
&	NULL
Ting	NULL
,	NULL
J.	NULL
P.-Y	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Crit	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

11	NULL
,	NULL
87-112	NULL
.	NULL

Tsang	NULL
,	NULL
S.	NULL
Y.	NULL
,	NULL
Nakanishi	NULL
,	NULL
M.	NULL
&	NULL
Peterlin	NULL
,	NULL
B.	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10	NULL
,	NULL
711-719	NULL
.	NULL

Sherman	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Basta	NULL
,	NULL
P.	NULL
V.	NULL
,	NULL
Moore	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
Brown	NULL
,	NULL
A.	NULL
M.	NULL
&	NULL
Ting	NULL
,	NULL
J.	NULL
P.-Y	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9	NULL
,	NULL
50-56	NULL
.	NULL

Zeleznik-Le	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Azizkhan	NULL
,	NULL
J.	NULL
C.	NULL
&	NULL
Ting	NULL
,	NULL
J.	NULL
P.-Y	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
1873-1877	NULL
.	NULL

Hume	NULL
,	NULL
C.	NULL
R.	NULL
&	NULL
Lee	NULL
,	NULL
J.	NULL
S.	NULL
(	NULL
1990	NULL
)	NULL
Tissue	NULL
Antigens	NULL
36	NULL
,	NULL
108-115	NULL
.	NULL

Reith	NULL
,	NULL
W.	NULL
,	NULL
Satola	NULL
,	NULL
S.	NULL
,	NULL
Sanchez	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Amaldi	NULL
,	NULL
I.	NULL
,	NULL
Lisowska-Grospierre	NULL
,	NULL
B.	NULL
,	NULL
Griscelli	NULL
,	NULL
C.	NULL
,	NULL
Hadam	NULL
,	NULL
M.	NULL
R.	NULL
&	NULL
Mach	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Cell	NULL
53	NULL
,	NULL
897-906	NULL
.	NULL

Reith	NULL
,	NULL
W.	NULL
,	NULL
Barras	NULL
,	NULL
E.	NULL
,	NULL
Satola	NULL
,	NULL
S.	NULL
,	NULL
Kobr	NULL
,	NULL
M.	NULL
,	NULL
Reinhart	NULL
,	NULL
D.	NULL
,	NULL
Sanchez	NULL
,	NULL
C.	NULL
H.	NULL
&	NULL
Mach	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86	NULL
,	NULL
4200-4204	NULL
.	NULL

Liou	NULL
,	NULL
H.-C.	NULL
,	NULL
Boothby	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Finn	NULL
,	NULL
P.	NULL
W.	NULL
,	NULL
Davidon	NULL
,	NULL
R.	NULL
,	NULL
Na-bavi	NULL
,	NULL
N.	NULL
,	NULL
Zeleznik-Le	NULL
,	NULL
N.	NULL
,	NULL
Ting	NULL
,	NULL
J.	NULL
P.-Y	NULL
.	NULL

&	NULL
Glimcher	NULL
,	NULL
L.	NULL
H.	NULL
(	NULL
1990	NULL
)	NULL
Science	NULL
247	NULL
,	NULL
1581-1584	NULL
.	NULL

Reith	NULL
,	NULL
W.	NULL
,	NULL
Sanchez	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Kobr	NULL
,	NULL
M.	NULL
,	NULL
Silacci	NULL
,	NULL
P.	NULL
,	NULL
Berte	NULL
,	NULL
C.	NULL
,	NULL
Barras	NULL
,	NULL
E.	NULL
,	NULL
Fey	NULL
,	NULL
S.	NULL
&	NULL
Mach	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

4	NULL
,	NULL
1528-1540	NULL
.	NULL

Hooft	NULL
van	NULL
Huijsduijnen	NULL
,	NULL
R.	NULL
A.	NULL
M.	NULL
,	NULL
Bollekens	NULL
,	NULL
J.	NULL
,	NULL
Dorn	NULL
,	NULL
A.	NULL
,	NULL
Benoist	NULL
,	NULL
C.	NULL
&	NULL
Mathis	NULL
,	NULL
D.	NULL
(	NULL
1987	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

15	NULL
,	NULL
7265-7282	NULL
.	NULL

Hooft	NULL
van	NULL
Huijsduijnen	NULL
,	NULL
R.	NULL
,	NULL
Li	NULL
,	NULL
X.	NULL
Y.	NULL
,	NULL
Black	NULL
,	NULL
D.	NULL
,	NULL
Matthes	NULL
,	NULL
H.	NULL
,	NULL
Benoist	NULL
,	NULL
C.	NULL
&	NULL
Mathis	NULL
,	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

9	NULL
,	NULL
3119-3127	NULL
.	NULL

Didier	NULL
,	NULL
D.	NULL
K.	NULL
,	NULL
Schiffenbauer	NULL
,	NULL
J.	NULL
,	NULL
Woulfe	NULL
,	NULL
S.	NULL
L..	NULL
,	NULL
Zacheis	NULL
,	NULL
M.	NULL
&	NULL
Schwartz	NULL
,	NULL
B.	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85	NULL
,	NULL
7322-7326	NULL
.	NULL

Sherman	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Basta	NULL
,	NULL
P.	NULL
V.	NULL
,	NULL
Heguy	NULL
,	NULL
A.	NULL
,	NULL
Wloch	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
&	NULL
Ting	NULL
,	NULL
J.	NULL
P.-Y	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86	NULL
,	NULL
6739-6743	NULL
.	NULL

Zeleznik-Le	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Itoh-Lindstrom	NULL
,	NULL
Y.	NULL
,	NULL
Clark	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
Moore	NULL
,	NULL
T.	NULL
L.	NULL
&	NULL
Ting	NULL
,	NULL
J.	NULL
P.-Y	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
7677-7682	NULL
.	NULL

Servenius	NULL
,	NULL
B.	NULL
,	NULL
Rask	NULL
,	NULL
L.	NULL
&	NULL
Peterson	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

262	NULL
,	NULL
8759-8766	NULL
.	NULL

Basta	NULL
,	NULL
P.	NULL
V.	NULL
,	NULL
Sherman	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

&	NULL
Ting	NULL
,	NULL
J.	NULL
P.-Y	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85	NULL
,	NULL
8618-8622	NULL
.	NULL

Moses	NULL
,	NULL
H.	NULL
,	NULL
Panek	NULL
,	NULL
R.	NULL
B.	NULL
,	NULL
Benveniste	NULL
,	NULL
E.	NULL
N.	NULL
&	NULL
Ting	NULL
,	NULL
J.	NULL
P.-Y	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

148	NULL
,	NULL
3643-3651	NULL
.	NULL

Mueller	NULL
,	NULL
P.	NULL
R.	NULL
&	NULL
Wold	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Science	NULL
246	NULL
,	NULL
780-786	NULL
.	NULL

Kara	NULL
,	NULL
C.	NULL
J	NULL
.	NULL

&	NULL
Glimcher	NULL
,	NULL
L.	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
Science	NULL
252	NULL
,	NULL
709-712	NULL
.	NULL

Wikstrand	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
Grahmann	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
McComb	NULL
,	NULL
R.	NULL
D.	NULL
&	NULL
Bigner	NULL
,	NULL
D.	NULL
D.	NULL
(	NULL
1985	NULL
)	NULL
J.	NULL
Neuropathol	NULL
.	NULL

Exp	NULL
.	NULL

Neurol	NULL
.	NULL

44	NULL
,	NULL
229-241	NULL
.	NULL

Kunkel	NULL
,	NULL
T.	NULL
,	NULL
Roberts	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Zakour	NULL
,	NULL
T.	NULL
(	NULL
1987	NULL
)	NULL
Methods	NULL
Enzymol	NULL
.	NULL

154	NULL
,	NULL
367-382	NULL
.	NULL

Pfeifer	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Tanguay	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Steigerwald	NULL
,	NULL
S.	NULL
D.	NULL
&	NULL
Riggs	NULL
,	NULL
A.	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

4	NULL
,	NULL
1277-1287	NULL
.	NULL

Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Lebovitz	NULL
,	NULL
R.	NULL
M.	NULL
&	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1983	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11	NULL
,	NULL
1475-1489	NULL
.	NULL

Gerster	NULL
,	NULL
T.	NULL
,	NULL
Matthias	NULL
,	NULL
P.	NULL
,	NULL
Thali	NULL
,	NULL
M.	NULL
,	NULL
Jiricny	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Schaffner	NULL
,	NULL
W.	NULL
(	NULL
1987	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

6	NULL
,	NULL
1323-1330	NULL
.	NULL

Church	NULL
,	NULL
G.	NULL
M.	NULL
&	NULL
Gilbert	NULL
,	NULL
W.	NULL
(	NULL
1985	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
81	NULL
,	NULL
1991-1995	NULL
.	NULL

Dorn	NULL
,	NULL
A.	NULL
,	NULL
Boliekens	NULL
,	NULL
J.	NULL
,	NULL
Staub	NULL
,	NULL
A.	NULL
,	NULL
Benoist	NULL
,	NULL
C.	NULL
&	NULL
Mathis	NULL
,	NULL
D.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
50	NULL
,	NULL
863-872	NULL
.	NULL

Cogswell	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Basta	NULL
,	NULL
P.	NULL
V.	NULL
&	NULL
Ting	NULL
,	NULL
J.	NULL
P.-Y	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87	NULL
,	NULL
7703-7707	NULL
.	NULL

Sugamura	NULL
,	NULL
K.	NULL
,	NULL
Fujii	NULL
,	NULL
M.	NULL
,	NULL
Kannagi	NULL
,	NULL
M.	NULL
,	NULL
Sakitani	NULL
,	NULL
M.	NULL
,	NULL
Takeuchi	NULL
,	NULL
M.	NULL
&	NULL
Hinuma	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
34	NULL
,	NULL
221-228	NULL
.	NULL

Kemler	NULL
,	NULL
I	NULL
.	NULL

&	NULL
Schaffner	NULL
,	NULL
W.	NULL
(	NULL
1990	NULL
)	NULL
FASEB	NULL
J	NULL
.	NULL

4	NULL
,	NULL
1444-1449	NULL
.	NULL

Collins	NULL
,	NULL
T.	NULL
,	NULL
Korman	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Wake	NULL
,	NULL
C.	NULL
T.	NULL
,	NULL
Boss	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Kappes	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Fiers	NULL
,	NULL
W.	NULL
,	NULL
Ault	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Gimbrone	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Strominger	NULL
,	NULL
J.	NULL
L.	NULL
&	NULL
Pober	NULL
,	NULL
J.	NULL
S.	NULL
(	NULL
1984	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
81	NULL
,	NULL
4917-4921	NULL
.	NULL

Rosa	NULL
,	NULL
F.	NULL
,	NULL
Hafat	NULL
,	NULL
D.	NULL
,	NULL
Abadie	NULL
,	NULL
A.	NULL
,	NULL
Wallach	NULL
,	NULL
D.	NULL
,	NULL
Revel	NULL
,	NULL
M.	NULL
&	NULL
Fellous	NULL
,	NULL
M.	NULL
(	NULL
1983	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

2	NULL
,	NULL
1585-1589	NULL
.	NULL

Vilen	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
Cogswell	NULL
,	NULL
J.	NULL
P.	NULL
&	NULL
Ting	NULL
,	NULL
J.	NULL
P.-Y	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
2406-2415	NULL
.	NULL

Mirkovitch	NULL
,	NULL
J.	NULL
,	NULL
Decker	NULL
,	NULL
T.	NULL
&	NULL
Darnell	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Jr.	NULL
(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
1-9	NULL
.	NULL

